Table 2.

Hazard ratio (HR) and associated 95% confidence interval (95% CI) of mortality and progression (defined as time to next treatment) according to PD-L1 expression, and KRAS mutation status among stage III unresected NSCLC patients diagnosed 2000–2013 and registered in the Danish Lung Cancer Group clinical database^

Model	Adjusted HR* Mortality (95% CI)	Adjusted HR* Progression (95% CI)
PD-L1% tumor cell membrane staining (≥ 1% versus < 1%)	0.83 (0.63–1.10)	0.78 (0.58–1.05)
PD-L1 (continuous)	1.00 (0.99–1.00)	1.00 (0.99–1.00)
KRASm (vs wildtype)	1.06 (0.74–1.51)	1.06 (0.74–1.50)
PD-L1+ ICs (≥ 1% versus < 1%)	0.51 (0.39–0.68)	0.50 (0.38–0.66)
% ICs§ (continuous)	0.96 (0.93–0.99)	0.96 (0.93–0.99)

*Adjusted for age, sex, histology (adenocarcinoma versus other), Charlson comorbidity index score and age of the tumor specimen.

^§% ICs: % tumor infiltrating immune cells.

^NSCLC: non-small cell lung cancer; PD-L1: programmed cell death ligand 1; KRAS: Kirsten rat sarcoma virus.